Drug Profile
Research programme: human papillomavirus vaccine - GeoVax Labs
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator GeoVax Labs
- Developer GeoVax Labs; Virometix
- Class Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Combination therapy) in USA
- 28 Jun 2022 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in USA
- 13 Nov 2018 GeoVax Labs enters a collaboration with Virometix for development of a combination therapeutic vaccine for human papillomavirus (HPV) infection and related cancers